Uniqure NV
QURE26.237USD
+0.587+2.29%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.63BCap. mercado
PérdidaP/E TTM
Más Datos de Uniqure NV Compañía
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Información de Uniqure NV
Símbolo de cotizaciónQURE
Nombre de la empresaUniqure NV
Fecha de salida a bolsaFeb 05, 2014
Director ejecutivoKapusta (Matthew)
Número de empleados209
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónPaasheuvelweg 25a
CiudadAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1105 BP
Teléfono31202406000
Sitio Webhttps://www.uniqure.com/
Símbolo de cotizaciónQURE
Fecha de salida a bolsaFeb 05, 2014
Director ejecutivoKapusta (Matthew)
Ejecutivos de Uniqure NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+5858.00%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-4670.00%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Otro
64.55%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Otro
64.55%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
41.44%
Investment Advisor
27.86%
Hedge Fund
19.42%
Corporation
3.83%
Research Firm
3.16%
Venture Capital
1.48%
Individual Investor
1.47%
Pension Fund
0.91%
Private Equity
0.89%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
427
59.61M
95.69%
-2.25M
2025Q3
368
55.15M
89.53%
-7.50M
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
5.55M
8.9%
+4.74M
+591.04%
Sep 30, 2025
Avoro Capital Advisors LLC
4.44M
7.13%
+819.44K
+22.61%
Sep 30, 2025
RTW Investments L.P.
4.42M
7.1%
-733.26K
-14.22%
Sep 30, 2025
EcoR1 Capital, LLC
3.99M
6.4%
--
--
Sep 30, 2025
abrdn Inc.
2.94M
4.72%
+189.03K
+6.87%
Sep 30, 2025
Bristol Myers Squibb
2.39M
3.83%
--
--
Sep 30, 2024
Franklin Advisers, Inc.
1.98M
3.17%
+369.97K
+23.05%
Sep 30, 2025
State Street Investment Management (US)
1.44M
2.32%
+301.20K
+26.36%
Sep 30, 2025
Jennison Associates LLC
999.48K
1.6%
+859.42K
+613.61%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
2.12%
+68.87K
+5.49%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Global X Genomics & Biotechnology ETF
3.77%
WisdomTree BioRevolution Fund
3.51%
Virtus LifeSci Biotech Clinical Trials ETF
2.87%
Invesco NASDAQ Future Gen 200 ETF
2.23%
Alger Mid Cap 40 ETF
2.06%
State Street SPDR S&P Biotech ETF
1.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
ProShares Ultra Nasdaq Biotechnology
0.36%
Invesco Nasdaq Biotechnology ETF
0.36%
Franklin Genomic Advancements ETF
0.34%
Ver más
Global X Genomics & Biotechnology ETF
Proporción3.77%
WisdomTree BioRevolution Fund
Proporción3.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción2.87%
Invesco NASDAQ Future Gen 200 ETF
Proporción2.23%
Alger Mid Cap 40 ETF
Proporción2.06%
State Street SPDR S&P Biotech ETF
Proporción1.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.84%
ProShares Ultra Nasdaq Biotechnology
Proporción0.36%
Invesco Nasdaq Biotechnology ETF
Proporción0.36%
Franklin Genomic Advancements ETF
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
